Finasteride vs Accutane (Isotretinoin): Cost and Access Head-to-Head

What Each Drug Actually Does

Finasteride and isotretinoin do not compete for the same patient. Finasteride is a 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), slowing follicle miniaturization in androgenetic alopecia (AGA). Isotretinoin is a retinoid that suppresses sebaceous gland activity and normalizes follicular keratinization, producing durable remission of nodular cystic acne.

Finasteride: Mechanism and Approved Uses

The FDA approved finasteride 1 mg (Propecia) for male AGA in 1997 [1]. At that dose, finasteride reduces scalp DHT by approximately 60%, arresting the hormonal cascade responsible for progressive follicle miniaturization. A separate 5 mg formulation (Proscar) carries FDA approval for benign prostatic hyperplasia [1].

Finasteride works continuously. Stopping treatment typically reverses any gains within 9 to 12 months because the underlying androgen sensitivity of the follicle is not corrected, only suppressed [2].

Isotretinoin: Mechanism and Approved Uses

The FDA approved oral isotretinoin for severe recalcitrant nodular acne in 1982 [3]. Its mechanism is distinct: isotretinoin shrinks sebaceous glands by up to 90% during a treatment course, reduces Cutibacterium acnes colonization indirectly, and normalizes keratinocyte differentiation [3].

Strauss et al. (Arch Dermatol 1984, N=150) demonstrated that a cumulative dose of 120 to 150 mg/kg produced durable remission in the majority of severe cystic acne patients, often after a single course [4]. That cumulative-dose target still anchors current dosing practice.

The Evidence Base for Each Drug

No head-to-head randomized controlled trial comparing finasteride to isotretinoin exists. The drugs treat different diagnoses, so synthesizing across their separate trial programs is the appropriate approach.

Finasteride Evidence: The Kaufman 5-Year Trial

Kaufman et al. (J Am Acad Dermatol 1998) followed 279 men with vertex AGA on finasteride 1 mg daily for five years [2]. At year two, 83% of treated men maintained or increased hair count versus 28% of placebo patients. At year five, the treated group showed a mean increase of 277 hairs in a 1-inch diameter circle compared to baseline, while placebo patients lost an average of 127 hairs. Discontinuation within this cohort confirmed that cessation reversed the benefit within approximately one year [2].

That five-year dataset, combined with a 1996 two-year phase III trial [5] and the 2011 Cochrane systematic review on androgenetic alopecia interventions [6], forms the foundation of current AGA guidelines from the American Academy of Dermatology.

Isotretinoin Evidence: Strauss and the Cumulative-Dose Concept

Strauss et al. (Arch Dermatol 1984) enrolled 150 patients with severe nodular acne in one of the first rigorous isotretinoin trials [4]. Patients receiving a cumulative dose of 120 to 150 mg/kg achieved remission rates that were maintained for years after the course ended, a finding replicated in subsequent studies. A 2020 Cochrane review of oral isotretinoin for acne confirmed that high-dose regimens produce higher remission rates, with relative risk of relapse reduction compared to low-dose continuous therapy [7].

The FDA's current prescribing information for isotretinoin specifies the 120 to 150 mg/kg cumulative target, directly citing this body of evidence [3].

Cost Comparison: What Patients Actually Pay

Cost is one of the most frequently searched dimensions of this comparison, and the answer differs sharply between the two drugs.

Finasteride Cost

Generic finasteride 1 mg is among the least expensive oral prescription medications in the United States. GoodRx pricing as of early 2025 puts a 30-day supply at $10 to 30 at most major pharmacies without insurance. Some telehealth platforms offering finasteride subscriptions bundle the prescription and medication for $20 to 40 per month including shipping.

Brand-name Propecia (discontinued by Merck in the US market for commercial reasons) no longer has a widely available reference price, but legacy brand versions in other markets run $60 to 90 per month. Because generic bioequivalence has been established and the FDA has approved multiple generic manufacturers [1], there is no clinical reason to choose brand over generic for most patients.

The long treatment duration matters for total cost. At $20 per month over five years, finasteride costs approximately $1,200. Patients who respond well may take the medication indefinitely.

Isotretinoin Cost

Isotretinoin's cost is far more variable. Generic isotretinoin (Claravis, Amnesteem, Myorisan, Absorica generic) runs roughly $50 to 150 per month depending on dose, which scales with body weight. A 70 kg patient targeting 1 mg/kg/day pays less than a 90 kg patient on the same per-kilogram protocol.

Brand-name Absorica (with the proprietary lipid formulation that improves absorption without a high-fat meal) can reach $600 to 800 per month without insurance [3]. A typical 16 to 20 week course at the target cumulative dose therefore costs $800 to 3,200 brand-name, or $400 to 1,500 generic, before insurance.

Most commercial insurance plans cover generic isotretinoin for FDA-approved indications. Medicaid coverage varies by state. The manufacturer of Absorica offers a patient assistance program, and the generic manufacturers offer copay cards through their respective programs.

The table below summarizes cost across common scenarios.

| Scenario | Monthly Cost (USD, approximate) | Total Course or Annual Cost | |---|---|---| | Finasteride 1 mg generic, no insurance | $10 to 30 | $120 to 360 per year (ongoing) | | Finasteride via telehealth subscription | $20 to 40 | $240 to 480 per year | | Isotretinoin generic, 70 kg patient, 1 mg/kg/day | $50 to 100 | $800 to 2,000 per course | | Isotretinoin generic, 90 kg patient, 1 mg/kg/day | $90 to 150 | $1,440 to 3,000 per course | | Absorica brand, 70 kg patient | $400 to 700 | $6,400 to 14,000 per course (rare without insurance) |

Access Requirements: iPLEDGE vs. Standard Prescription

This is where the two drugs differ most sharply in practical terms. Finasteride requires only a licensed prescriber and a standard pharmacy. Isotretinoin requires enrollment in the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program, mandated by the FDA because of isotretinoin's teratogenicity [3].

The iPLEDGE REMS Program

The FDA requires every prescriber, dispensing pharmacy, and patient who uses isotretinoin to register with iPLEDGE [3]. The program's primary goal is preventing fetal exposure, given that isotretinoin is pregnancy category X and causes severe birth defects at any dose, including a single pill taken during organogenesis [3].

Requirements differ by reproductive potential:

• Patients who cannot become pregnant (assigned male at birth or post-menopausal) must have two iPLEDGE confirmations and complete monthly surveys.
• Patients who can become pregnant must use two simultaneous forms of contraception, complete two negative pregnancy tests (one at least 30 days before starting), and re-confirm negative pregnancy status monthly before each 30-day prescription is released.
• Each monthly prescription must be filled within a 7-day window after the prescriber's confirmation; if the window lapses, the process restarts.

A 2022 analysis published in JAMA Dermatology found that the transition to an online-only iPLEDGE system caused dispensing delays for 6.4% of patients, with disproportionate impact on patients at safety-net clinics [8]. The FDA acknowledged these access concerns and has since revised some portal navigation features.

Telehealth Access for Isotretinoin

Several telehealth platforms now offer isotretinoin prescribing under iPLEDGE. The regulatory requirements do not change: pregnancy tests must still be performed at a CLIA-certified laboratory, and pharmacies must still be iPLEDGE-certified. Telehealth removes the in-office visit barrier but does not eliminate lab work or the monthly confirmation window. Patients in rural areas have reported that lab access remains the primary bottleneck even when prescriber access is digital.

Telehealth Access for Finasteride

Finasteride carries no REMS obligation. A telehealth clinician may prescribe it after a standard clinical intake and photo review. No lab work is required before initiation, though baseline labs are reasonable clinical practice. Prescriptions can be sent to any pharmacy. This makes finasteride one of the most accessible prescription treatments in the AGA space. The American Academy of Dermatology's 2019 guidelines for AGA list finasteride 1 mg daily as a first-line agent for men [9].

Side-Effect Profiles and How They Affect Access Decisions

Side effects are a secondary driver of access decisions, particularly for patients who research both drugs before their consultation.

Finasteride: Sexual Side Effects and Post-Finasteride Syndrome

The 1998 Kaufman trial reported a 1.8% incidence of decreased libido and 1.3% incidence of erectile dysfunction in the finasteride 1 mg group versus 1.3% and 0.7% in placebo, respectively [2]. These rates are low but not zero.

A contested syndrome called Post-Finasteride Syndrome (PFS) describes persistent sexual, neurological, and psychological symptoms after stopping the drug. The FDA updated the finasteride label in 2012 to include persistent sexual dysfunction as a possible adverse event [1]. The incidence of persistent symptoms is debated; a 2020 systematic review in JAMA Dermatology estimated the rate of persistent post-treatment sexual dysfunction at 1 to 2% [10].

Prescribers should document this discussion before initiating therapy.

Isotretinoin: Teratogenicity, Mood, and Mucocutaneous Effects

Isotretinoin's teratogenicity is categorical. The FDA label states that the drug is contraindicated in pregnancy and requires the iPLEDGE program because of the severity and certainty of harm [3]. Mucocutaneous dryness (cheilitis, xerosis, epistaxis) affects nearly all patients and is dose-dependent.

The relationship between isotretinoin and depression has been studied extensively. A 2019 systematic review in the British Journal of Dermatology covering 31 studies found no consistent causal link between isotretinoin and depression in acne patients, with several studies showing mood improvement as acne resolved [11]. Prescribers should screen for baseline mood disorders and monitor during therapy regardless.

Triglyceride elevation occurs in roughly 25% of patients and is reversible with dose reduction or cessation [3]. Baseline and monthly lipid panels are standard practice.

Who Gets Which Drug: Practical Patient Selection

The decision is rarely a choice between finasteride and isotretinoin. Each drug maps to a different diagnosis.

Patients Who Need Finasteride

A man with Hamilton-Norwood stage II, IV androgenetic alopecia confirmed by clinical exam or trichoscopy is a candidate for finasteride 1 mg daily. The American Academy of Dermatology 2019 guideline rates it a Grade A recommendation for men [9]. Finasteride is not FDA-approved for AGA in women, though off-label use exists in specific clinical contexts, particularly post-menopausal women, under careful monitoring [9].

Patients Who Need Isotretinoin

A patient with nodular or cystic acne (Grade III, IV) that has failed at least one course of an oral antibiotic (typically tetracycline-class, 3 to 6 months) meets the standard threshold for isotretinoin consideration. The American Academy of Dermatology acne guideline recommends isotretinoin for severe, scarring, or antibiotic-resistant acne [12]. Enrollment in iPLEDGE must precede the first prescription.

When Both Conditions Co-Exist

A male patient may have both androgenetic alopecia and severe acne. These conditions can be treated concurrently, one with finasteride 1 mg daily (continuous) and one with a time-limited isotretinoin course. There is no pharmacokinetic interaction of clinical significance between the two drugs. Coordination between the prescribers or use of a single clinician managing both is straightforward when both conditions meet treatment criteria.

Insurance Coverage and Prior Authorization

Insurance dynamics further complicate access.

Finasteride 1 mg for AGA is frequently excluded from formulary coverage because hair loss is classified as cosmetic by many commercial insurers. Patients often pay out of pocket. At generic prices of $10 to 30 per month, this is manageable for most patients.

Finasteride 5 mg for BPH carries better insurance coverage because it treats a medical condition with documented morbidity. Some patients and prescribers have prescribed the 5 mg tablet with instructions to split it into quarters, reducing per-dose cost further, though pill-splitting affects dose precision.

Isotretinoin prescribed for severe nodular acne (the FDA-approved indication) generally receives insurance coverage, subject to prior authorization in many plans. Insurers may require documentation of at least one failed antibiotic course before approving isotretinoin. The prior authorization process adds 5 to 15 business days before the patient can start. Combined with the iPLEDGE enrollment and mandatory pregnancy tests, total lead time from consultation to first pill may be 3 to 6 weeks for patients who can become pregnant.

The FDA's iPLEDGE portal is available at FDA iPLEDGE information and provides current enrollment steps and certified pharmacy lists [3].

Switching Between These Drugs

Patients occasionally ask whether they can switch from one drug to the other, usually because of side effects or treatment failure.

Switching from Finasteride to Isotretinoin

This switch indicates two different conditions are being addressed sequentially or that acne has emerged during finasteride therapy. There is no washout required before starting isotretinoin. The prescriber should initiate iPLEDGE enrollment at the point the decision is made, understanding that 3 to 6 weeks may pass before isotretinoin is dispensed.

Finasteride may be continued during isotretinoin therapy with monitoring. No major pharmacokinetic interaction is documented in the literature.

Switching from Isotretinoin to Finasteride

If a patient completing an isotretinoin course also has AGA, finasteride 1 mg may be started after the isotretinoin course ends. Some clinicians prefer a 30-day observation window post-isotretinoin before adding another oral medication, though this is not guideline-mandated. Isotretinoin itself can cause a temporary telogen effluvium-like shedding during the course, which resolves after completion [13]. Initiating finasteride before the post-isotretinoin shedding resolves may obscure assessment of finasteride's early effect.

A Note on Off-Label and Compounded Formulations

Both drugs exist in compounded and off-label forms that affect cost and access.

Compounded topical finasteride (0.25% solution) is prescribed off-label for AGA, with some evidence suggesting comparable DHT suppression at the scalp with lower systemic DHT reduction, potentially reducing sexual side-effect risk [14]. Compounded topical finasteride is not FDA-approved, and quality control varies by compounding pharmacy. Monthly cost for compounded topical finasteride runs $30 to 80.

Low-dose isotretinoin (0.1 to 0.3 mg/kg/day) is used off-label for moderate acne and sebaceous conditions. Evidence for this approach is growing. A 2020 randomized trial in the Journal of the American Academy of Dermatology (N=120) found that low-dose isotretinoin (20 mg every other day) achieved remission in 78% of patients with moderate acne at 24 weeks, with a significantly lower adverse-event profile than standard dosing [15]. Off-label low-dose isotretinoin still requires iPLEDGE enrollment.